NCT06422637Not yet recruiting
A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
INFORM: A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
Source: ClinicalTrials.gov · Last updated 21 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This project aims to establish the MERCURY pilot screening program as part of the "Love Lung Project," employing a novel concept of lung cancer screening with the assistance of low-dose computer tomography (LDCT). By using clinical pathology as the gold standard, it will parallelly compare the performance (with a sensitivity of ≥90%) of the MERCURY early lung cancer screening model against the LDCT-only screening group within the "Love Lung Project." Ultimately, the objective is to reduce the proportion of overtreatment, achieve earlier staging, and extend patient survival, thus enhancing clinical value.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 5944 (estimated)
- First submitted
- 14 May 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Diseases
- Lung cancer
- NCT number
- NCT06422637
What you commit to
- Study type: Interventional
- Planned participants: 5944
- From 1 Jun 2024 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals currently suffering from a febrile illness, or who have had an acute inflammatory disease episode requiring internal medicine treatment within the last 14 days prior to blood draw;
- Individuals who have taken corticosteroids orally or through intravenous injection within the 14 days prior to blood draw;
- Organ transplant recipients or those who have previously received a non-autologous (allogeneic) bone marrow or stem cell transplant;
Other illness
- Individuals currently diagnosed with any tumors other than lung cancer, or who have a history of cancer;
- Any other clinically significant disease or condition considered by the researchers to potentially affect adherence to the protocol, impact the patient's ability to provide informed consent, or render the patient unsuitable for participation in the clinical trial.
Other
- Pregnant women;
- Those who have undergone LDCT/CT screening within the past 1-3 years;
- Individuals in poor health or not suitable for blood drawing;
Who the study is looking for
- Age greater than 40 years old and less than 75 years old, regardless of gender.
- Sign the informed consent form.
Age in the registry: 40 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.